Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TATI Study: Switching from preserved latanoprost to preservative-free tafluprost/timolol in glaucoma/ocular hypertension
KCT0010003Phase 4Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tafluprost + timolol in open-angle glaucoma (OAG), ocular hypertension, normal tension glaucoma (NTG), sponsored by Santen Pharmaceutical. Started Jul 2022; status: completed.
02
Drugs
tafluprost + timolol
03
Conditions
open-angle glaucoma (OAG)ocular hypertensionnormal tension glaucoma (NTG)
Beyond the preview
Go deeper on KCT0010003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010003.